Nanoform Finland (FRA:4YL) Short-Term Debt: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4YL Nanoform Finland PLC FRA:4YL
63 GF Score
Price €0.86
GF Value €1.72
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nanoform Finland Short-Term Debt?

Nanoform Finland FRA:4YL +2.02% 63 Short-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:4YL with a GF Score™ of 63/100 and a GF Value™ of €1.72 (Possible Value Trap). The stock has 4 warning signs investors should review.

Nanoform Finland's Short-Term Debt for the quarter that ended in Mar. 2026 was €0.00 Mil.

Nanoform Finland Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Nanoform Finland Short-Term Debt Related Terms

Nanoform Finland Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Nanoform Finland's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanoform Finland Short-Term Debt Chart

Nanoform Finland Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nanoform Finland Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:4YL
63GF Score
Nanoform Finland PLC FRA:4YL
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.00 Mil mean?
Nanoform Finland (FRA:4YL) has a Short-Term Debt of €0.00 Mil as of Mar. 2026.
Is Nanoform Finland's Short-Term Debt too high?
Nanoform Finland's current Short-Term Debt is €0.00 Mil. Overall, Nanoform Finland has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanoform Finland's Short-Term Debt compare to VRTX and REGN?
Nanoform Finland's Short-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Nanoform Finland's current Short-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoform Finland stock overvalued right now?
Based on GuruFocus' analysis, Nanoform Finland (FRA:4YL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.72, compared to a current price of €0.86 — trading 50.1% below its estimated fair value. The current Short-Term Debt is €0.00 Mil. Nanoform Finland's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Nanoform Finland (FRA:4YL), the current Short-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanoform Finland (FRA:4YL) Overvalued in 2026?

Based on GuruFocus' analysis, Nanoform Finland stock appears to be undervalued. The current stock price of €0.86 is trading 50.1% below its estimated GF Value™ of €1.72. GuruFocus considers Nanoform Finland to be Possible Value Trap.

Key valuation signals for FRA:4YL:

  • Short-Term Debt: €0.00 Mil
  • GF Value™: €1.72 vs. price of €0.86 (50.1% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the FRA:4YL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanoform Finland Business Description

Other Exchanges NANOFS:SwedenNANOFH:Finland
Address Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
63GF Score

Get the complete analysis for FRA:4YL

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.86
Price
€1.72
GF Value